Eucrates Biomedical Acquisition (EUCR) Short Interest Ratio & Short Volume

Short interest is the volume of Eucrates Biomedical Acquisition shares that have been sold short but have not yet been closed out or covered. As of August 15th, traders have sold 16,800 shares of EUCR short. 0.16% of Eucrates Biomedical Acquisition's shares are currently sold short. Learn More on Eucrates Biomedical Acquisition's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EUCR shares currently have a short interest ratio of 1.0. Learn More on Eucrates Biomedical Acquisition's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.16% of Eucrates Biomedical Acquisition's floating shares are currently sold short.

Eucrates Biomedical Acquisition saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 16,800 shares, an increase of 31.3% from the previous total of 12,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Eucrates Biomedical Acquisition currently has issued a total of 4,210,000 shares. Some of Eucrates Biomedical Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eucrates Biomedical Acquisition currently has a public float of 10,790,000 shares.

0.16% of Eucrates Biomedical Acquisition's shares are currently sold short. Here is how the short interest of companies in the industry of "holding & other investment offices" compare to Eucrates Biomedical Acquisition: Hennessy Capital Investment Corp. VI (0.03%), Plum Acquisition Corp. III (0.02%), Zalatoris Acquisition Corp. (0.00%), Concord Acquisition Corp II (0.00%), Papaya Growth Opportunity Corp. I (0.01%), Direct Selling Acquisition Corp. (0.00%), Integrated Rail and Resources Acquisition Corp. (0.00%), Global Lights Acquisition Corp (0.29%), Evergreen Co. (0.02%), byNordic Acquisition Co. (0.13%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Corporation ($4.13 billion), Charter Communications, Inc. ($3.94 billion), Coinbase Global, Inc. ($2.38 billion), Lucid Group, Inc. ($2.30 billion), T. Rowe Price Group, Inc. ($2.22 billion), Williams-Sonoma, Inc. ($2.02 billion), Plug Power, Inc. ($1.94 billion), Chesapeake Energy Co. ($1.91 billion), Unity Software Inc. ($1.82 billion), and Rivian Automotive, Inc. ($1.74 billion). View all of the most shorted stocks.

Short selling EUCR is an investing strategy that aims to generate trading profit from Eucrates Biomedical Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Eucrates Biomedical Acquisition occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EUCR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EUCR, twice per month. The most recent reporting period available is August, 15 2022.